S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:GH

Guardant Health Stock Forecast, Price & News

$106.92
-0.33 (-0.31%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$106.01
$111.48
50-Day Range
$92.89
$131.27
52-Week Range
$91.19
$181.07
Volume
766,844 shs
Average Volume
983,204 shs
Market Capitalization
$10.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.46
30 days | 90 days | 365 days | Advanced Chart
Receive GH News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.


Guardant Health logo

About Guardant Health

Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Redwood City, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
864
Year Founded
N/A

Sales & Book Value

Annual Sales
$286.73 million
Book Value
$6.98 per share

Profitability

Net Income
$-253.78 million
Net Margins
-118.80%
Pretax Margin
-117.77%

Debt

Price-To-Earnings

Miscellaneous

Free Float
95,760,000
Market Cap
$10.87 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
11/27/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/23/2022

MarketRank

Overall MarketRank

2.44 out of 5 stars

Medical Sector

153rd out of 1,391 stocks

Medical Laboratories Industry

5th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Guardant Health (NASDAQ:GH) Frequently Asked Questions

Is Guardant Health a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Guardant Health stock.
View analyst ratings for Guardant Health
or view top-rated stocks.

How has Guardant Health's stock been impacted by Coronavirus?

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GH shares have increased by 69.8% and is now trading at $106.92.
View which stocks have been most impacted by COVID-19
.

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Guardant Health
.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $0.16. The company earned $94.80 million during the quarter, compared to the consensus estimate of $92.59 million. Guardant Health had a negative net margin of 118.80% and a negative trailing twelve-month return on equity of 44.55%. Guardant Health's revenue for the quarter was up 26.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.78) EPS.
View Guardant Health's earnings history
.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $360 million-$370 million, compared to the consensus revenue estimate of $366.68 million.

What price target have analysts set for GH?

11 equities research analysts have issued 1-year price targets for Guardant Health's stock. Their forecasts range from $155.00 to $190.00. On average, they anticipate Guardant Health's stock price to reach $169.90 in the next twelve months. This suggests a possible upside of 58.9% from the stock's current price.
View analysts' price targets for Guardant Health
or view top-rated stocks among Wall Street analysts.

Who are Guardant Health's key executives?

Guardant Health's management team includes the following people:
  • Helmy Eltoukhy, Chairman & Co-Chief Executive Officer (LinkedIn Profile)
  • AmirAli H. Talasaz, President, Co-Chief Executive Officer & Director
  • Michael Bell, Chief Financial Officer
  • Darya Chudova, Senior Vice President-Technology
  • Kumud Kalia, Chief Information Officer

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health CEO Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among Guardant Health's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (5.47%), BlackRock Inc. (5.48%), Capital Research Global Investors (5.20%), Viking Global Investors LP (4.82%), Coatue Management LLC (2.76%) and Credit Suisse AG (1.76%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Samir Kaul, Stanley J Meresman and Stanley J Meresman.
View institutional ownership trends for Guardant Health
.

Which institutional investors are selling Guardant Health stock?

GH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Deutsche Bank AG, Blue Water Life Science Advisors LLC, Jane Street Group LLC, Janus Henderson Group PLC, Polar Capital Holdings Plc, Bank of Nova Scotia, and FIL Ltd. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Helmy Eltoukhy, Ian T Clark, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health
or view top insider-selling stocks.

Which institutional investors are buying Guardant Health stock?

GH stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Morgan Stanley, Viking Global Investors LP, American Century Companies Inc., Moore Capital Management LP, Macquarie Group Ltd., Pura Vida Investments LLC, and Coatue Management LLC.
View insider buying and selling activity for Guardant Health
or or view top insider-buying stocks.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $106.92.

How much money does Guardant Health make?

Guardant Health has a market capitalization of $10.87 billion and generates $286.73 million in revenue each year. The company earns $-253.78 million in net income (profit) each year or ($4.05) on an earnings per share basis.

How many employees does Guardant Health have?

Guardant Health employs 864 workers across the globe.

What is Guardant Health's official website?

The official website for Guardant Health is www.guardanthealth.com.

Where are Guardant Health's headquarters?

Guardant Health is headquartered at 505 PENOBSCOT DR., REDWOOD CITY CA, 94063.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at (855) 698-8887, via email at [email protected], or via fax at 888-974-4258.


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.